1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radioimmunotherapy Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Non Hodgkin Lymphoma (NHL)
1.2.3 Follicular Lymphoma
1.2.4 Solid Tumors
1.2.5 Breast Cancer
1.2.6 Ovarian Cancer
1.2.7 Osteosarcoma
1.2.8 Neuroblastoma
1.2.9 Prostate Cancer
1.3 Market by Application
1.3.1 Global Radioimmunotherapy Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Tumor Antigens
1.3.3 Radionuclides
1.3.4 Antibodies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Radioimmunotherapy Market Perspective (2017-2028)
2.2 Radioimmunotherapy Growth Trends by Region
2.2.1 Radioimmunotherapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Radioimmunotherapy Historic Market Size by Region (2017-2022)
2.2.3 Radioimmunotherapy Forecasted Market Size by Region (2023-2028)
2.3 Radioimmunotherapy Market Dynamics
2.3.1 Radioimmunotherapy Industry Trends
2.3.2 Radioimmunotherapy Market Drivers
2.3.3 Radioimmunotherapy Market Challenges
2.3.4 Radioimmunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radioimmunotherapy Players by Revenue
3.1.1 Global Top Radioimmunotherapy Players by Revenue (2017-2022)
3.1.2 Global Radioimmunotherapy Revenue Market Share by Players (2017-2022)
3.2 Global Radioimmunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Radioimmunotherapy Revenue
3.4 Global Radioimmunotherapy Market Concentration Ratio
3.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radioimmunotherapy Revenue in 2021
3.5 Radioimmunotherapy Key Players Head office and Area Served
3.6 Key Players Radioimmunotherapy Product Solution and Service
3.7 Date of Enter into Radioimmunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Radioimmunotherapy Breakdown Data by Type
4.1 Global Radioimmunotherapy Historic Market Size by Type (2017-2022)
4.2 Global Radioimmunotherapy Forecasted Market Size by Type (2023-2028)
5 Radioimmunotherapy Breakdown Data by Application
5.1 Global Radioimmunotherapy Historic Market Size by Application (2017-2022)
5.2 Global Radioimmunotherapy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Radioimmunotherapy Market Size (2017-2028)
6.2 North America Radioimmunotherapy Market Size by Country (2017-2022)
6.3 North America Radioimmunotherapy Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Radioimmunotherapy Market Size (2017-2028)
7.2 Europe Radioimmunotherapy Market Size by Country (2017-2022)
7.3 Europe Radioimmunotherapy Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Radioimmunotherapy Market Size (2017-2028)
8.2 Asia-Pacific Radioimmunotherapy Market Size by Country (2017-2022)
8.3 Asia-Pacific Radioimmunotherapy Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Radioimmunotherapy Market Size (2017-2028)
9.2 Latin America Radioimmunotherapy Market Size by Country (2017-2022)
9.3 Latin America Radioimmunotherapy Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radioimmunotherapy Market Size (2017-2028)
10.2 Middle East & Africa Radioimmunotherapy Market Size by Country (2017-2022)
10.3 Middle East & Africa Radioimmunotherapy Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Bayer Healthcare Pharmaceuticals
11.1.1 Bayer Healthcare Pharmaceuticals Company Detail
11.1.2 Bayer Healthcare Pharmaceuticals Business Overview
11.1.3 Bayer Healthcare Pharmaceuticals Radioimmunotherapy Introduction
11.1.4 Bayer Healthcare Pharmaceuticals Revenue in Radioimmunotherapy Business (2017-2022)
11.1.5 Bayer Healthcare Pharmaceuticals Recent Development
11.2 BioSynthema
11.2.1 BioSynthema Company Detail
11.2.2 BioSynthema Business Overview
11.2.3 BioSynthema Radioimmunotherapy Introduction
11.2.4 BioSynthema Revenue in Radioimmunotherapy Business (2017-2022)
11.2.5 BioSynthema Recent Development
11.3 Clarity Pharmaceuticals
11.3.1 Clarity Pharmaceuticals Company Detail
11.3.2 Clarity Pharmaceuticals Business Overview
11.3.3 Clarity Pharmaceuticals Radioimmunotherapy Introduction
11.3.4 Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2017-2022)
11.3.5 Clarity Pharmaceuticals Recent Development
11.4 Curasight
11.4.1 Curasight Company Detail
11.4.2 Curasight Business Overview
11.4.3 Curasight Radioimmunotherapy Introduction
11.4.4 Curasight Revenue in Radioimmunotherapy Business (2017-2022)
11.4.5 Curasight Recent Development
11.5 Endocyte
11.5.1 Endocyte Company Detail
11.5.2 Endocyte Business Overview
11.5.3 Endocyte Radioimmunotherapy Introduction
11.5.4 Endocyte Revenue in Radioimmunotherapy Business (2017-2022)
11.5.5 Endocyte Recent Development
11.6 Immunomedics
11.6.1 Immunomedics Company Detail
11.6.2 Immunomedics Business Overview
11.6.3 Immunomedics Radioimmunotherapy Introduction
11.6.4 Immunomedics Revenue in Radioimmunotherapy Business (2017-2022)
11.6.5 Immunomedics Recent Development
11.7 Molecular Insight Pharmaceuticals
11.7.1 Molecular Insight Pharmaceuticals Company Detail
11.7.2 Molecular Insight Pharmaceuticals Business Overview
11.7.3 Molecular Insight Pharmaceuticals Radioimmunotherapy Introduction
11.7.4 Molecular Insight Pharmaceuticals Revenue in Radioimmunotherapy Business (2017-2022)
11.7.5 Molecular Insight Pharmaceuticals Recent Development
11.8 Nordic Nanovector
11.8.1 Nordic Nanovector Company Detail
11.8.2 Nordic Nanovector Business Overview
11.8.3 Nordic Nanovector Radioimmunotherapy Introduction
11.8.4 Nordic Nanovector Revenue in Radioimmunotherapy Business (2017-2022)
11.8.5 Nordic Nanovector Recent Development
11.9 PDL Biopharma
11.9.1 PDL Biopharma Company Detail
11.9.2 PDL Biopharma Business Overview
11.9.3 PDL Biopharma Radioimmunotherapy Introduction
11.9.4 PDL Biopharma Revenue in Radioimmunotherapy Business (2017-2022)
11.9.5 PDL Biopharma Recent Development
11.10 Philogen
11.10.1 Philogen Company Detail
11.10.2 Philogen Business Overview
11.10.3 Philogen Radioimmunotherapy Introduction
11.10.4 Philogen Revenue in Radioimmunotherapy Business (2017-2022)
11.10.5 Philogen Recent Development
11.11 RadioMedix
11.11.1 RadioMedix Company Detail
11.11.2 RadioMedix Business Overview
11.11.3 RadioMedix Radioimmunotherapy Introduction
11.11.4 RadioMedix Revenue in Radioimmunotherapy Business (2017-2022)
11.11.5 RadioMedix Recent Development
11.12 Stella Pharma
11.12.1 Stella Pharma Company Detail
11.12.2 Stella Pharma Business Overview
11.12.3 Stella Pharma Radioimmunotherapy Introduction
11.12.4 Stella Pharma Revenue in Radioimmunotherapy Business (2017-2022)
11.12.5 Stella Pharma Recent Development
11.13 Telix Pharmaceuticals
11.13.1 Telix Pharmaceuticals Company Detail
11.13.2 Telix Pharmaceuticals Business Overview
11.13.3 Telix Pharmaceuticals Radioimmunotherapy Introduction
11.13.4 Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2017-2022)
11.13.5 Telix Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
